Mesoblast Stock Net Income
| MEOBF Stock | USD 1.90 0.55 40.74% |
Fundamental analysis of Mesoblast allows traders to better anticipate movements in Mesoblast's stock price by examining its financial health and performance throughout various phases of its business cycle.
Mesoblast |
Mesoblast Company Net Income Analysis
Mesoblast's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Mesoblast Net Income | (91.35 M) |
Most of Mesoblast's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mesoblast is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Mesoblast reported net income of (91.35 Million). This is 126.77% lower than that of the Healthcare sector and 230.41% lower than that of the Biotechnology industry. The net income for all United States stocks is 116.0% higher than that of the company.
Mesoblast Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mesoblast's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Mesoblast could also be used in its relative valuation, which is a method of valuing Mesoblast by comparing valuation metrics of similar companies.Mesoblast is currently under evaluation in net income category among its peers.
Mesoblast Fundamentals
| Return On Equity | -0.16 | |||
| Return On Asset | -0.0688 | |||
| Operating Margin | (9.53) % | |||
| Current Valuation | 504.31 M | |||
| Shares Outstanding | 736.58 M | |||
| Shares Owned By Insiders | 11.76 % | |||
| Shares Owned By Institutions | 26.13 % | |||
| Price To Earning | (6.34) X | |||
| Price To Book | 0.92 X | |||
| Price To Sales | 68.10 X | |||
| Revenue | 10.21 M | |||
| Gross Profit | (53.36 M) | |||
| EBITDA | (70.3 M) | |||
| Net Income | (91.35 M) | |||
| Cash And Equivalents | 60.45 M | |||
| Cash Per Share | 0.08 X | |||
| Total Debt | 91.62 M | |||
| Debt To Equity | 0.21 % | |||
| Current Ratio | 1.36 X | |||
| Book Value Per Share | 0.71 X | |||
| Cash Flow From Operations | (65.78 M) | |||
| Earnings Per Share | (0.14) X | |||
| Number Of Employees | 77 | |||
| Beta | 2.43 | |||
| Market Capitalization | 544.31 M | |||
| Total Asset | 662.14 M | |||
| Retained Earnings | (288 M) | |||
| Working Capital | 40 M | |||
| Current Asset | 71 M | |||
| Current Liabilities | 31 M | |||
| Z Score | 3.0 | |||
| Net Asset | 662.14 M |
About Mesoblast Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mesoblast's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mesoblast using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mesoblast based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Additional Information and Resources on Investing in Mesoblast Pink Sheet
When determining whether Mesoblast offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesoblast's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesoblast Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesoblast Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more detail on how to invest in Mesoblast Pink Sheet please use our How to Invest in Mesoblast guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.